Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients

Division of Digestive and Liver Diseases, Columbia University Presbyterian Hospital, New York, NY 10032, USA.
Alimentary Pharmacology & Therapeutics (Impact Factor: 5.73). 11/2008; 29(3):273-8. DOI: 10.1111/j.1365-2036.2008.03878.x
Source: PubMed


Adalimumab, at an induction dose of 160/80 mg followed by 40 mg every other week is approved for treatment of refractory Crohn's disease (CD) and for patients with loss of response to infliximab.
To evaluate the indications for adalimumab, the proportion of inflammatory bowel disease patients who require dose escalation and to identify whether this strategy is effective in inducing or maintaining remission.
Patients prescribed adalimumab for CD were identified and included for analysis, if they had follow-up of at least 6 weeks. Adalimumab dose was escalated if patients had return of symptoms prior to next dose. Clinical judgment was used to determine severity of disease. A second GI physician confirmed disease severity as determined by the first physician.
A total of 48 out of 60 patients met inclusion criteria. Adalimumab was used to treat CD in 47/48 (98%) and ulcerative colitis in one (2%). Most patients had moderate 30/48 (63%) or severe 17/48 (35%) disease. Prior infliximab exposure was present in 42/48 (88%). Adalimumab dose escalation occurred in 14/48 (29%) within an average time of 2.2 months (s.d. 1.5 months). A majority of patients who required dose escalation, nine of 14 (64%) did not improve clinically. Steroids could be discontinued in three of 16 (18.8%). Clinical improvement was noted in 21/48 (43.8%) and one of 48 (2%) patients achieved clinical remission. Adverse drug reactions necessitated drug discontinuation in four of 48 (8%) of patients.
This retrospective review from a single academic medical centre suggests that a minority of patients, who cannot be maintained on 40 mg every other week, of adalimumab benefit from an increased dose. This suggests the need for a treatment with an alternative mode of action in anti-TNF failures.

7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Three biological therapies targeting TNFα are currently marketed with similar efficacies and risks for the treatment of Crohn’s disease. To date, only infliximab is approved for the treatment of ulcerative colitis. Natalizumab, a humanized antialpha4 integrin is effective for the treatment of Crohn’s disease but compromised by a risk of progressive multifocal encephalopathy. Induction and regularly scheduled maintenance therapy optimizes clinical results for all biological agents. Immunogenicity is an important factor for all biologicals and can be reduced by high-dose induction and regularly scheduled maintenance therapy. Concomitant immunosuppression reduces immunogenicity but does not improve efficacy for patients with refractory disease but may improve therapeutic efficacy for patients who are immunosuppressive naive. Infectious complications are increased in patients on concomitant corticosteroids and/or immunosuppressants. Dose modification is needed in many patients to maintain remissions. Switching between anti-TNF agents is effective for patients who develop immunogenicity but is less effective for patients who lose response in the presence of circulating biological concentrations. The ultimate positioning of biological agents will be determined by future ­studies assessing comparative effectiveness of different therapeutic strategies in both Crohn’s disease and ulcerative colitis.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Start of the above-titled section of the conference proceedings record.
    Digest of Technical Papers - IEEE International Solid-State Circuits Conference 01/2004; DOI:10.1109/ISSCC.2004.1332771
  • [Show abstract] [Hide abstract]
    ABSTRACT: A simple processing technology for oxide confined vertical-cavity surface-emitting lasers fabrication is reported in this article. Results of the burn-in test up to the present-day show that the high temperature lifetime of the fabricated devices exceeded 3300 hours. The eye diagrams show that the devices can be modulated up to 10 Gbps.
    Lasers and Electro-Optics, 2003. CLEO/Pacific Rim 2003. The 5th Pacific Rim Conference on; 01/2004
Show more


7 Reads